Drug Profile
BAY 399437
Latest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action Serine endopeptidase inhibitors; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis; Shock
Most Recent Events
- 13 Oct 2004 This compound is still in active development
- 31 Dec 2003 Preclinical trials in Shock (unspecified route)
- 06 Sep 2000 Preclinical development for Cystic fibrosis (Unknown route)